KLRA 最新10-Q变化
将 KLRA 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-12 与上一份 10-Q · 2026-05-26
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +28 | −15 | ~14 | 50 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 3 |
| 法律诉讼 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
| 风险因素 | 文字有新增/删除 | +1 | 0 | ~11 | 581 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-12
In July 2026, Hengrui reported positive topline data from its Phase 3 trial of once-weekly ribupatide injection (4 mg and 2 mg) in type 2 diabetes, or T2D, patients with inadequate glycemic control despite diet and exercise interventions in China. Ribupatide injection showed significant reductions i…
In July 2026, Hengrui reported positive topline data from two Phase 3 clinical trials of KAI-7535 (being developed by Hengrui in Greater China as HRS-7535). In Hengrui’s Phase 3 trial in adults with obesity in China, participants taking HRS-7535 180 mg achieved a mean weight loss of up to 11.1% from…
Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net loss wa…
deficit of $558.8 million. We expect to continue to incur significant expenses and recognize operating losses for at least the next several years as we advance our product candidates through later stage clinical development and seek regulatory approval of our product candidates. In addition, if we o…
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our operations with proceeds from outside sources, wi…
相对上期删除的文字 · 来源:10-Q · 2026-05-26
In May 2026, we and Hengrui reported positive topline data from Hengrui’s Phase 3 type 2 diabetes, or T2D, clinical trial of KAI-7535 (being developed by Hengrui in Greater China as HRS-7535). In the first of multiple Phase 3 trials, HRS-7535 met the primary endpoint by demonstrating a significant h…
In May 2026, we and Hengrui reported positive topline data from Hengrui’s Phase 1 single ascending and multiple ascending dose trial of KAI-4729 (being developed by Hengrui in Greater China as HRS-4729). HRS-4729 demonstrated safety and tolerabilty data consistent with GLP-1-based treatments. In a s…
Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net loss wa…
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations with proceeds from outside sources, with a majority of…
as to manage our nonclinical, clinical and manufacturing development activities. These employees work across multiple product candidates and, therefore, we do not track these costs by product candidate.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-08-12
could put our patent rights at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation and proceedings, there is a risk that some of our confidential information co…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议